The first study to demonstrate the benefits of CB2 activation in atherosclerosis was performed in ApoE−/− mice using low doses of the cannabinoid ∆9-THC, which diminished inflammation and blocked the progression of the disease [149]. The gene discussed is CNR2; the disease is atherosclerosis.